van der Meulen

Aug 10, 2024 | mdpi.com | Christian Selinger |van der Meulen

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Apr 4, 2024 | cds.cern.ch | van der Meulen

Home > Terbium-149 production: a focus on yield and quality improvement towards preclinical application TitleTerbium-149 production: a focus on yield and quality improvement towards preclinical applicationAuthor(s) Favaretto, C (Basel U. ; PSI, Villigen) ; Grundler, P V (PSI, Villigen) ; Talip, Z (PSI, Villigen) ; Köster, U (Laue-Langevin Inst.

Feb 17, 2024 | ijhpm.com | van der Meulen

Document Type : Review Article Authors Woranan Witthayapipopsakul 1, 2 Shaheda Viriyathorn 2 Salisa Rittimanomai 2 Jan van der Meulen 1 Viroj Tangcharoensathien 2 Ipek Gurol-Urganci 1 Anne Mills 3 1 Department of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK 2 International Health Policy Program, Ministry of Public Health, Nonthaburi, Thailand 3 London School of Hygiene and Tropical Medicine, London, UK...

Jan 10, 2024 | cds.cern.ch | van der Meulen

Home > Articles & Preprints > Committee Documents > CERN Experiments Committees > INTC - ISOLDE and Neutron Time-of-flight Committee > INTC Public Documents > Terbium-149 for targeted alpha therapy Report number CERN-INTC-2024-020 ; INTC-P-593-ADD-2 Title Terbium-149 for targeted alpha therapy Project Manager/Technical Coordinator van der Meulen, Nick; Johnston, Karl Author(s) Van der Meulen, Nick (Paul Scherrer Institut, Villigen – ETH Zürich, Switzerland) ; Johnston, Karl (CERN, ISOLDE)...

Dec 1, 2023 | academic.oup.com | van der Meulen |location VUmc |Ggz InGeest

Glucocorticoids are widely used drugs because of their anti-inflammatory effects, with an annual prevalence estimated at approximately 24% in 2022 in The Netherlands, including systemic, inhaled, nasal, and topical glucocorticoids (1).